AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Nervous system disorder

stroke disorder

A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.

🔔 Follow weekly
🧬8138genes / proteins with evidence
💊228drugs and clinical candidates
🧪12+recruiting trials worldwide
✅45approved
📈1filed for approval
❤️

Understand stroke disorder

Heart and blood vessels · Arteries that narrow and clog
🎓 Learn more

What it is

A stroke happens when there is a loss of blood flow to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die within a few minutes. This can cause lasting brain damage, long-term disability, or even death.

If you think that you or someone else is having a stroke, call 911 right away. Immediate treatment may save someone's life and increase the chances for successful rehabilitation and recovery.

What are the types of stroke?

From MedlinePlus: Stroke (US National Library of Medicine) ↗

❤️ Heart and blood vessels: Heart and blood vessel (cardiovascular) diseases affect how blood flows. The most common is coronary artery disease, where the arteries that feed the heart become narrow.

❓ Why it happens

  • A fatty plaque slowly builds up inside artery walls (atherosclerosis), over many years.
  • High LDL cholesterol, high blood pressure, smoking, diabetes, obesity, inactivity, family history and age all speed it up.

🫀 What it does to the body

  • Narrow arteries starve the heart muscle of oxygen, causing chest pain.
  • If a plaque breaks, a clot can block the artery completely: a heart attack - or a stroke in the brain.
  • A weakened heart may not pump well enough (heart failure).

🧱 Why it is hard to cure

  • Plaque builds silently for decades; the first sign can be a heart attack.
  • Heart muscle that dies does not grow back.
  • The risk factors are very common and need lifelong control.

🚀 What research is trying now

  • New ways to lower cholesterol, such as PCSK9-blocking medicines and twice-a-year injections.
  • Medicines against lipoprotein(a), an inherited risk factor, in late trials.
  • Gene editing to switch off cholesterol genes for good, in early trials.
  • AI that spots heart risk early from an ECG or a scan.

General information about heart and blood vessels, reviewed by people; it does not describe any one person. Below: the evidence for stroke disorder itself.

🤖

AI briefing

Where the science on stroke disorder stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens stroke disorder.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
F2 coagulation factor II, thrombinPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.75
ACE angiotensin I converting enzymePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.70
PDE3A phosphodiesterase 3APROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.70
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.69
F5 coagulation factor VPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.68
COL4A1 collagen type IV alpha 1 chainantibodyother🧊 AlphaFold structure ↗ 0.65
COL4A2 collagen type IV alpha 2 chainPROTACantibodyother🧊 AlphaFold structure ↗ 0.63
PDE4B phosphodiesterase 4BPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.63
PTGS2 prostaglandin-endoperoxide synthase 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.62
P2RY12 purinergic receptor P2Y12PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.62
F10 coagulation factor XPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.62
CACNA1C calcium voltage-gated channel subunit alpha1 CPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.61
AGTR1 angiotensin II receptor type 1PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.61
ADRB2 adrenoceptor beta 2PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.61
PTGS1 prostaglandin-endoperoxide synthase 1PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.60

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to stroke disorder, by how far it has got
Approved · 20
Aliskiren FumarateRenin inhibitorApproved
AlteplaseTissue-type plasminogen activator exogenous proteinApproved
Amlodipine BesylateVoltage-gated L-type calcium channel blockerApproved
ApixabanCoagulation factor X inhibitorApproved
AspirinCyclooxygenase inhibitorApproved
AtenololBeta-1 adrenergic receptor antagonistApproved
Show all 20
Atorvastatin CalciumHMG-CoA reductase inhibitorApproved
Azilsartan KamedoxomilType-1 angiotensin II receptor antagonistApproved
Benazepril HydrochlorideAngiotensin-converting enzyme inhibitorApproved
BendroflumethiazideThiazide-sensitive sodium-chloride cotransporter inhibitorApproved
Candesartan CilexetilType-1 angiotensin II receptor antagonistApproved
CelecoxibCyclooxygenase-2 inhibitorApproved
ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitorApproved
ClopidogrelPurinergic receptor P2Y12 antagonistApproved
Clopidogrel BisulfatePurinergic receptor P2Y12 antagonistApproved
DabigatranThrombin inhibitorApproved
Dabigatran Etexilate MesylateThrombin inhibitorApproved
Dantrolene SodiumRyanodine receptor 1 antagonist; Ryanodine receptor 3 antagonistApproved
DipyridamoleEquilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitorApproved
EdoxabanCoagulation factor X inhibitorApproved
In phase 2 / 3 · 20
ColchicineTubulin inhibitorFiled for approval
AcetylleucinePhase 3
AmlodipineVoltage-gated L-type calcium channel blockerPhase 3
ArgatrobanThrombin inhibitorPhase 3
AtorvastatinHMG-CoA reductase inhibitorPhase 3
Botulinum Toxin Type ASynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzymePhase 3
Show all 20
CandesartanType-1 angiotensin II receptor antagonistPhase 3
CarbogenPhase 3
CilostazolPhosphodiesterase 3A inhibitorPhase 3
CitalopramSerotonin transporter inhibitorPhase 3
ClomethiazoleGABA-A receptor; anion channel positive allosteric modulatorPhase 3
Dabigatran EtexilateThrombin inhibitorPhase 3
Damoctocog Alfa PegolCoagulation factor VIII exogenous proteinPhase 3
Deferoxamine MesylatePhase 3
DextrosePhase 3
DonepezilAcetylcholinesterase inhibitorPhase 3
DoxazosinAdrenergic receptor alpha-1 antagonistPhase 3
EptifibatideIntegrin alpha-IIb/beta-3 inhibitorPhase 3
FluoxetineSerotonin transporter inhibitorPhase 3
GlyburideSulfonylurea receptor 1, Kir6.2 blockerPhase 3
Early trials · 18
Autologous Cord BloodPhase 1/2
Darbepoetin AlfaErythropoietin receptor agonistPhase 1/2
Epoetin AlfaErythropoietin receptor agonistPhase 1/2
Epoetin BetaErythropoietin receptor agonistPhase 1/2
EscitalopramSerotonin transporter inhibitorPhase 1/2
ActoveginPhase 1
Show all 18
Ascorbic AcidPhase 1
BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitorPhase 1
Ils-920Phase 1
PegcetacoplanComplement C3 inhibitorPhase 1
PsilocybinSerotonin 2a (5-HT2a) receptor agonistPhase 1
PyridoxinePhase 1
Sodium NitratePhase 1
ThiaminePhase 1
BenserazideDOPA decarboxylase inhibitorEarly phase 1
CyproheptadineHistamine H1 receptor antagonistEarly phase 1
DuloxetineSerotonin transporter inhibitor; Norepinephrine transporter inhibitorEarly phase 1
TizanidineAdrenergic receptor alpha-2 agonistEarly phase 1
🧪

Recruiting trials

Worldwide, open to new patients now
Research on the Effectiveness of Neurorehabilitation After StrokeNCT06753006 · NA · 📍 SamaraA Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Part…NCT07704840 · Phase 2 · 📍 Elkins ParkEarly Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Sub…NCT07588997 · NA · 📍 TaipeiPassive Robots for Stroke Rehabilitation: A Feasibility StudyNCT07218276 · NA · 📍 Ann ArborCombining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIANCT06591338 · Phase 3 · 📍 Kafr ash ShaykhDelayed Versus Early Antihyperglycemic Treatment for Severe StrokeNCT07501533 · Phase 2 · 📍 WuhuPhoton-counting CT for Intracranial Stent AssessmentNCT07769814 · n/a · 📍 BeijingIntravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stro…NCT07776873 · Phase 3 · 📍 HefeiEMG-Directed Virtual-Reality Training for Motor Stroke RehabilitationNCT07705256 · NA · 📍 LondonChina Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypeNCT04974151 · Phase 4 · 📍 BengbuIntra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)NCT04664946 · NA · 📍 ShenyangBilateral Robot-assisted Upper Extremity Rehabilitation on Motor Recovery in People With Subacute StrokeNCT06906588 · NA · 📍 Cassino Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy